Clinical trials: Oral Chemotherapy
Head and Neck Cancer
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113399
- Testing
- filgrastim, cisplatin, docetaxel
- Where
- 125 sites in United States
- Volunteers
- 15 people
- Sponsor
- Radiation Therapy Oncology Group
Mucositis Oral
Oral Self Care Protocol and Oral Mucositis
Objective: This study was conducted in order to examine the effect of oral self-care protocol based on Orem's Self-Care Deficiency Theory on oral mucositis and self-care agency.
- Trial name
- OSCP and OM (NCT06049511)
- Testing
- oral self care protocol, standard care
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ege University
Chronic Myeloproliferative Disorders, Kidney Cancer
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who…
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00036712
- Testing
- management of therapy complications, pain therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Permanent Chemotherapy-induced Alopecia
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
An open label, pilot study involving the use of low dose oral minoxidil to treat permanent chemotherapy-induced alopecia.
- Trial name
- NCT03831334
- Testing
- oral minoxidil
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Pancreatic Cancer
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic pancreatic cancer who have failed at least one prior chemotherapy regimen in either the neoadjuvant, adjuvant, or first-line metastatic…
- Trial name
- NCT00568646
- Testing
- MKC-1
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- CASI pharmaceuticals, Inc.
Oral Cancer
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using…
- Trial name
- NCT05456022
- Testing
- Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT), Doxorubicin chemotherapeutic drug as a positive control
- Where
- Egypt
- Volunteers
- 1,000,000 people
- Sponsor
- Cairo University
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003602
- Testing
- cytarabine, etoposide, idarubicin
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Riverside Haematology Group
Myelodysplastic Syndromes (MDS)
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
The main aim of the study is to see if signs and symptoms of myelodysplastic syndromes disappear when treated with pevonedistat combined with decitabine and cedazuridine.
- Trial name
- PEVOBINE (NCT04985656)
- Testing
- Pevonedistat, Decitabine, Cedazuridine
- Sponsor
- Takeda
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread…
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8
- Trial name
- NCT05408845
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 154 sites in United States
- Volunteers
- 146 people
- Sponsor
- NRG Oncology
Colorektal Cancer
Self-Management of Colon and Rectal Cancer Patients Receiving Oral Chemotherapy
Objective: This study aims to evaluate the effectiveness of a message-based intervention on self-management among patients with colorectal cancer receiving oral chemotherapy treatment. H1.
- Trial name
- Self Managemet (NCT07851675)
- Testing
- Messaging Intervention Effectiveness, control group
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Ozlem
Chemotherapy Induced Mucositis, Mouth Pain
A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain
The purpose of this study is to characterize the pharmacokinetics and tolerability of buprenorphine patches in children who require opioid pain relief for moderate to severe mouth pain.
- Trial name
- BUP1501 (NCT00947466)
- Testing
- Buprenorphine
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Mundipharma Research Limited
Head and Neck Cancer, Oral Mucositis
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
The purpose of this study is to evaluate the efficacy and safety of SBG vs placebo on oral mucositis in head and neck cancer patients undergoing radiation therapy.
- Trial name
- NCT00790322
- Testing
- SBG
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Biotec Pharmacon ASA
Mucositis Oral
Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis
Oral mucositis consequences can range from pain, decreased oral intake, impaired speech and swallowing to adverse events as severe as septicemia, increased hospitalization, and G-tube feeding A wide variety of agents have been…
- Trial name
- NCT04303312
- Testing
- Benzydamine Hydrochloride, Solcoseryl and pumpkin seed oil
- Volunteers
- 54 people
- Sponsor
- Ghada zaki
Multiple Myeloma
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.
- Trial name
- NCT03748953
- Testing
- Ixazomib
- Where
- 10 sites in China
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Head and Neck Cancer
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib after chemoradiotherapy may kill more tumor cells.
- Trial name
- NCT00079053
- Testing
- erlotinib hydrochloride, adjuvant therapy
- Where
- 2 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Mucositis
Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
Oral mucositis is a debilitating side effect for oncology patients and there is a clear need for new therapeutic options. The lozenges containing Lactobacillus brevis CD2 proved a potential new alternative for the prevention of…
- Trial name
- NCT01707641
- Testing
- CD#2, bicarbonate sodium mouthwash
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- S. Andrea Hospital
Cancer
Medico-economic Evaluation of the ONCORAL Program for Ambulatory Patients Under Oral Anticancer Drugs Versus Usual Care
Economic impact of cancer treatments is increasing for years: increase of number of patients (385 000 new occurrences in 2015), increase of life expectancies, chronicization of diseases and increase of therapeutic innovation…
- Trial name
- ONCORAL-PRME (NCT03660670)
- Testing
- ONCORAL therapeutic education, Standard of care
- Where
- France
- Volunteers
- 215 people
- Sponsor
- Hospices Civils de Lyon
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death worldwide with 1.4 millions of deaths every years.
- Trial name
- ONC-MANILA12 (NCT02176369)
- Testing
- Vinorelbine
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Healthy Volunteers
A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
The purpose of this study is to assess the relative bioavailability of a TAK-648 tablet compared with a TAK-648 oral solution, and to assess the effect of food on the bioavailability of a TAK-648 tablet in healthy participants.
- Trial name
- NCT02480439
- Testing
- TAK-648 Tablet, TAK-648 Oral Solution
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Head Cancer, Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
- Trial name
- AURACCO (NCT05946577)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris